March 19, 2007 – Acadia Pharma soared after releasing data from a Phase II test of its schizophrenia drug candidate, ACP-103. The drug is a novel 5-HT2A inverse antagonist that was effective when given with low doses of commonly prescribed anti-psychotics. Because the high doses of the already available drugs are associated with side effects, the news was positive for ACP-103. Acadia stock jumped 97% higher, rising $6.46 to $13.15. Company officials said they would seek a partner as they move toward a Phase III trial of ACP-103 for this indication. More details...
